🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

After 9/11, NATO's Article 5 was invoked for the first (and only) time ever by the United States. Troops from the UK, Canada, Germany, France, Italy, the Netherlands, Denmark, Australia, Spain, Poland, Norway, Romania, Turkey, New Zealand, Estonia, Lithuania, Latvia, Ukraine,

Conan O’Brien dings Donald Trump: Anora is having a good night. Two wins already. I guess Americans are excited to see somebody finally stand up to a powerful Russian.” #Oscars

Omg. Now Trudeau is trolling Trump. This. Is. Awesome. ❤️🇨🇦

Donald Trump has called for MSNBC Host Rachel Maddow to resign due to her critical coverage of the administration. He continues to try and attack the free press - but we won’t let him win. RETWEET if you stand with @Maddow against Trump!

I remember very distinctly when Covid vaccines were rolled out. As an ER doctor, I saw that people who got vaccinated stopped getting super sick. And they were way less likely to die. I also saw that people who didn’t get vaccinated got much much sicker, much quicker. They

BREAKWATER shows that 1L EC+FOLFOX results in mPFS 12.8m and mOS 30.3m!! 🥹🥲 That mOS far exceeded my greatest hope for this study. A great turning point for a bad actor 🙌👊🏻 #ASCO25

Day 3 #ASCO2025 Before LBA1 + LBA5 break cover, it’s already been a 🙌 2 days for #GIonc !🧐 BREAKWATER: nejm.org/doi/full/10.10… DESTINY-Gastric04 nejm.org/doi/full/10.10… PANOVA-3 ascopubs.org/doi/10.1200/JC… LEAP-015: ascopubs.org/doi/10.1200/JC… ClaudinCarT : thelancet.com/journals/lance…

Matterhorn falters on OS EFS HR 0.71 🧪 NEJM MATTERHORN Trial — Periop Durvalumab + FLOT in Resectable Gastric/GEJ Cancer n=948 | Global Phase 3 | FLOT backbone 🎯 Primary Endpoint: Event-Free Survival (EFS) 📊 2-yr EFS: 67.4% vs 58.5% 🕒 Median EFS: NR vs 32.8 mo 🧮 HR 0.71

#ASCO25 Neoadjuvant or adjuvant in dMMR colon cancer? Looks like we’ll be discussing this at length today. Let’s start with this comparison👇

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

🔬 ATOMIC trial follow-up data for dMMR stage III colon cancer🥼 📢 ASCO 2025 Update from Chicago 🏙️ ✅ Atezolizumab + mFOLFOX6 shows sustained 3-yr DFS of 86.4% vs 76.6% with mFOLFOX6 alone (HR: 0.50, p<0.0001). 📰ARTICLE: oncologytube.com/atomic-trial-a… 📺YOUTUBE:

I have been naming this for years as the top patient intervention to reduce the risk of colorectal cancer recurrence. Ever since this study was published: pubmed.ncbi.nlm.nih.gov/16822844/

#ASCO25 #Plenary ASCO LBA1 - ATOMIC - mFOLFOX6 +\- atezoX1y in stage 3 dMMR colon cancer Alliance for Clinical Trials in Oncology n=712, 54% high-risk ➡️3yDFS 86.4% vs 76.7%, HR 0.50p<0.001 ➡️OS immature -2 deaths in combo arm 👏 Frank Sinicrope, MD Questions remain: 📌do we need FOLFOX? 📌 do we need 1

If I can achieve the following result with neoadj 2 doses of nivo + 1 dose of ipi, I see no compelling reason to prefer 6 months of chemotherapy plus 1 year of ICI in the adjuvant setting. NICHE-2👇

Great discussion by Myriam Chalabi on ATOMIC I still feel and like many of others, 2 cycles of neoadjuvant IO are enough, for all pts with stage 3 dMMR ca colon pts . We have learned this from melanoma , that neo adjuvant IO is way better than Adjuvant IO Sorry, ATOMIC

What a great study!!!

Worthy of a plenary session — CO.21 shows that exercise reduces recurrence after adjuvant and improves OS

The NCCN has included adjuvant atezolizumab (for 1 year) in the treatment of stage pT2c–III dMMR colon cancer. Given the positive trial results, its inclusion is certainly appropriate. However, the guideline adopts a somewhat conservative stance regarding neoadjuvant ICI use,

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

Organ preservation is definitely not controversial with this group of KOLs. Fantastic to have trailblazing surgeons like them pushing the 💉 (literally). Julio Garcia Aguilar Laura Fernandez Geerard Beets #ESMOGI25 #ESMOAmbassadors ESMO - Eur. Oncology